Addendum to policies, guidelines and consensus statements: pharmacologic management of type 2 diabetes: 2015 interim update.

An interim update of the chapter titled Pharmacologic Management of Type 2 Diabetes in the 2013 Clinical Practice Guidelines was recently published in Canadian Journal of Diabetes; it incorporates the sodium glucose linked transporter 2 (SGLT2) inhibitor class (1). Since the publication of the update, another SGLT2 inhibitor has received notice of compliance from Health Canada (2). The article’s Figure 2, which shows the antihyperglycemic medications and considerations for renal function, has been updated. References